MUC1 and neoplasm: An inverted cytokine receptor composed of the IL-4 receptor exodomain fused to the IL-7 receptor endodomain improved the persistence and anti-tumor activity of anti-MUC1 CAR T-cells against an IL-4-secreting breast cancer CDX model [53].